High Signal Podcasts Evidence ledger
Method
Browse
← Back to evidence

Evidence receipt / belief

Published · transcript-backed

David Rosenthal: belief

22 Jan 2024 Acquired Novo Nordisk (Ozempic)

“I had to dig a bit to figure out the exact economic splits. I believe that the final ratio was 62% Novo and 38% Nordisk.”

— David Rosenthal

Source trail

Everything needed to verify it.

Speaker
David Rosenthal
Attribution
Verified speaker
Claim type
belief
Recorded
22 Jan 2024
Publisher
Acquired

Transcript context

…That is the current state of what happens when many people or most people go and fill a prescription. Bringing it back to when the Novo Nordisk merger finally happens, this is the background on the go-to market side, at least in the US, and then there's also the background on the infrastructure side, thanks to genetic engineering, where scale now really matters. Both companies are now on much more of an even footing. In January 1989, the Novo Nordisk merger is finally announced. It's a dual merger of both the operating companies and their respective foundations. The two foundations merged into one, and the two operating companies merged into one as well. I had to dig a bit to figure out the exact economic splits. I believe that the final ratio was 62% Novo and 38% Nordisk. Novo was still the larger majority institution here, but this is a far cry from when discussions first started 10 years ago and Nordisk was this little. Hey, we're buying you for cash, essentially. No, now it's like, this is really a 60/40 merger. It's crazy. The two guys that split off, went to be cowboys, and start their own little competitor, even though they didn't have the license, ended up creating the bigger company.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.

Search evidence